North America Rubella Vaccine Market

North America Rubella Vaccine Market Size & Growth (2023 to 2028):

As per the research report, the size of the North America Rubella Vaccine (Human Diploid Cell) market was valued at USD XX Million in 2023 and is expected to reach USD XX Million by 2028 at XX % CAGR during the forecast period 2023 to 2028.

A rise in congenital defects caused by rubella infection is driving the demand for rubella vaccines, which is resulting in an increase in incidences and prevalence of the disease. Viral replication occurs in the respiratory tract and is transmitted by respiratory secretions that are aerosolized in closed areas. Symptoms usually appear 10-12 days after infection, which is characterized by fever. Individuals on immunosuppressive medications should not receive Rubella vaccines because the virus can replicate and cause infection. MMR (measles, mumps, rubella) vaccine, which is administered at least 28 days before conception, is important for preventing congenital rubella syndrome and congenital defects.

Nearly 1lakh people are affected by rubella each year due to an increased incidence of infections. Market demand is the sole factor influencing the price of the vaccine.

Government and non-government activities are expected to drive market growth during the forecast period. There hasn't been a specific treatment for rubella yet, so the vaccine is expected to gain a large market in the coming years since the disease has only been proven by vaccination. Rotavirus, hepatitis, polio, varicella, meningococcal illness, MMR, Human Papilloma Virus (HPV) infection, influenza, pneumococcal disease, Diphtheria, Tetanus, and Pertussis, and others are among the disease indications covered in the vaccine market. In addition, pneumococcal infections have increased in frequency, propelling the growth of this market.

In addition, government and non-government organizations are collaborating on the development of a Rubella vaccine which is expected to influence the market growth positively.

As industrialization expands, air pollution in the region is predicted to increase the prevalence of airborne infections. Rubella is the most prevalent illness among those who have not received a vaccination. The market's expansion is expected to be aided by patients' safety and stringent regulations. 

However, there are side effects associated with the vaccine, which are expected to limit the market growth. In addition, other factors such as high production costs, a limited number of vaccines, precise manufacturing, and a gap between demand and supply during epidemics are hampering the market growth. 

Some of the factors that impede the growth of the rubella vaccine markets are reactions related to vaccinations and insufficient yield with high selectivity of human diploid cells while constructing rubella vaccines.

This research report on the North America Rubella Vaccine Market has been segmented and sub-segmented into the following categories:

By End User:

• Pediatric Rubella Vaccine
• Adult Rubella Vaccine
• Traveler Rubella Vaccine

By Country:

• U.S
• Canada
• Rest of North America

Geographically, the North America dominated the worldwide rubella vaccine market during the projected period, and it is anticipated to record a significant share during the forecast period. The market is expected to be driven by the factors such as the increasing government immunization initiatives and manufacturing assistance from manufacturers, the presence of the advanced healthcare sector, and favourable reimbursement policies.

Further, Market growth is predicted due to high patient safety standards and a strong regulatory environment. In addition, as part of its strategy to eradicate the disease, the government is making continuous investments on a large scale to have a long-term impact.

The U.S rubella vaccine market held the largest share of the market owing to the rising incidence of rubella infection, increasing research and development activities, and high healthcare spending is boosting the market growth. In addition, the government and private organizations are increasing investments and initiatives for the development of MMR vaccine is encouraging market growth. 

On the other hand, the Canadian rubella vaccine market is projected to record owing to the increasing incidence of pneumococcal infections, growing awareness, and robust regulations and patient safety.

KEY MARKET PLAYERS

Companies playing a dominant role in the North America Rubella Vaccine Market profiled in this report are Merck & Co., Inc., GlaxoSmithKline Plc, Chiron Corporation (Novartis), Sanofi-Aventis, Serum Institute of India, Astellas Pharma Inc., AstraZeneca Plc. (Medimmune, LLC.), CSL Limited, Pfizer Inc., and Berna Biotech (Crucell).,